We are proud that Mayo Clinic has been recognized once again as a leader in healthcare, a reflection of the unwavering commitment of our staff and their dedication to excellence, innovation, and putting patients first. health.usnews.com/best-hospitals

What defines platinum ineligibility (sPI) in NSCLC? Post Hoc Validation of Ph III IPSOS trial JTO & JTO CRR: - sPI: PS3, age>80yrs, PS2+ or age≥70+ comorbidities - 405pts (89%) sPI+ - these pts had ⬆️OS, ⬇️TRAEs with atezo Solange Peters OncoAlert #LCSM jto.org/article/S1556-…

Savolitinib+osi in post-osi EGFR+ NSCLC with MET+, Ph II SAVANNAH trial Annals of Oncology: - 365pts (n=80 primary efficacy pop, IHC3+/>90%, FISH10+) - ORR 56.3% mDoR 7.1m, mPFS 7.8m Good option. MET testing likely a rate-limiting step OncoAlert #LCSM annalsofoncology.org/article/S0923-…

Key lung cancer 🫁 milestones to watch in 2025. 🔗 Follow us for latest clinical trials and insights from the world of oncology 👉 clin.larvol.com #LARVOL #LungCancer #WorldLungCancerDay #CancerResearch #Oncology #ClinicalTrials #CancerData #OncologyInsights #WLCD |

‼️Today is #WorldLungCancerDay. It’s an “ERA OF #HOPE” for #Patients with #LungCancer. We celebrate the great progress, but we still have a long way to go. We will keep advancing #CancerResearch & #CancerCare. We will keep the fight FOR and WITH our fearless patients. #LCSM

🚨 New review in Nature Reviews Cancer dives into the complexity of #SCLC: nature.com/articles/s4156… Highlights: ▪️Marked heterogeneity & plasticity ▪️NOTCH-driven NE↔non-NE shifts 💉 DLL3-targeted therapy emerging 🧬 Molecular subtypes (ASCL1, NEUROD1, POU2F3) & biomarker under study

Tiziana Damiano Spuffy/Michiruka Stan {MAT}❤️‍🔥🍉 La stragrande maggioranza (praticamente tutte) delle raccolte fondi per “curarsi all’estero” sono truffe.

#WCLC25 Presidential FLAURA2 OS in 1L EGFR+ NSCLC: - mOS 47.5m v 37.6m (HR 0.77 p=0.02) - duration of osi 30.5m on osi+chemo v 21.2m osi- combo delays acq resistance? - 72% got 2L chemo- does this add ~9m? - all subgrps benefit (?BM, ?co-mtns) Congrats d.planchard @iaslc #LCSM

One of the biggest influences on my career is Dr. Ross Camidge - a mentor and friend, an intellectual giant in the field of lung cancer who was diagnosed with this unforgiving disease himself. We are all at risk - and must all work to move the field. news.cuanschutz.edu/cancer-center/…

🚨🔥OncoAlert Hot Off The Press. Just published JTO & JTO CRR, results of: ⭐️ #COCOON Trial 🔷The Very important #SupportiveCare randomized trial of: Enhanced Vs Standard #Prophylactic #Dermatologic Management during Tx with #Amivantamab/#Lazertinib in patients with #EGFR+

📖New online: JCO Sunvozertinib becomes the 1st TKI approved (🎉FDA, 2025🎉) for EGFR ex20ins NSCLC. 📊 ORR: 45–47% ⏱DoR: 11–13.8 mo 🔄Similar efficacy in near- vs. far-loop insertions 🧩ORR 25% in pre-treated with Amivantamab Sunvozertinib in Platinum-Pretreated NSCLC

🔄#WCLC25 REVIEW🔁 🔥CheckMate 77T: Patient-reported outcomes with perioperative nivolumab by nodal status in patients with resectable NSCLC 🎯Perioperative NIVO did not negatively impact HRQoL vs PBO 🎙️ Jonathan Spicer MD PhD #LCSM OncoAlert LARVOL IASLC cattendee.abstractsonline.com/meeting/21151/…

ALK inhibitors in #lungcancer

1/3 🫁 Lung - #EGFR 🫁 🫁 Advanced / Metastatic #EGFRm #NSCLC 🌟 Summary of clinical trials for 1st line EGFR-TKIs. 🌟 As of September 2025 🌟 EGFR-TKIs monotherapy

✅✅ A reminder by Dr. Rahaf Ajaj: She wasn’t on the Stanford list… but she made it to the Nobel stage. 🏅 Mary E. Brunkow, one of this year’s Nobel Prize winners in Medicine, has only 34 published papers and an H-index of 21. She never appeared in Stanford’s ranking of the

UNREST sIII NSCLC is a new hot topic -PACIFIC remains SoC Efforts to improve but: -Intensification IO consol ❌ -IO with CRT❌ -Promising data with i CTIO—>CRT🔆 Future: *SKS03❓ *Borderline unresect —> Resect: MDT Bridge❓ (ESMO) *Lots of challenges ✳️ rdcu.be/eJ9Lj

Review in JAMA on lung cancer in patients with no smoking history, who now make up about 20% of all new cases of lung cancer. The biology of these cancers is different, as is the treatment, but the gravity is the same. Read now at JAMA. jamanetwork.com/journals/jama/…

Lung Cancer in Nonsmoking Individuals - now out in JAMA 🫁 15-20% of lung cancers 🏭 Risk factors include environmental air pollution (PM2.5) and indoor cooking fumes 🎯Potentially actionable oncogene targets in majority of cases jamanetwork.com/journals/jama/…

Data from the Dutch cancer Registry on survival in patients with NSCLC and leptomeningeal metastases Lung Cancer Journal from Lizza Hendriks group. OS with best supportive care 1.3m, with chemo +/- IO ~8m, with targeted therapy 20.5m. Importance of testing. lungcancerjournal.info/article/S0169-…

Unfortunately, while DLL3 is widely expressed (93%+) in tumors post-SCLC transformation (ejcancer.com/action/showPdf…), it is not clearly an actionable or biologically relevant target for transformed SCLC. This is similar to EGFR alterations and anti-PD-1/PD-L1 therapies, despite high